Strategic isotope pathways
Thorium Atomics is building the Tesseract TGR first and foremost as a reactor platform for industrial heat, firm power, and long-term fuel diversification. That is the core case.
A thorium-capable reactor architecture can also do something strategically important beyond energy alone: it can create a pathway toward the production of high-value isotopes, including those relevant to medicine. A strategic extension of the platform, not the reason the platform exists.
Certain medical isotopes, especially alpha emitters such as Actinium-225, are increasingly important for targeted radiopharmaceutical applications. The key bottleneck is supply.
Ac-225 is an alpha-emitting radioisotope under active clinical investigation for targeted alpha therapy (TAT). Unlike conventional radiation treatments that affect broad areas of tissue, alpha particles travel only a few cell diameters, delivering intense, highly localized energy to cancer cells while largely sparing the surrounding healthy tissue.
The current standard for targeted prostate cancer therapy, Lutetium-177, delivers beta radiation across millimeters of tissue. Ac-225 delivers alpha particles across less than 100 micrometers. In clinical studies, Ac-225 has shown remarkable responses even in patients who had exhausted all other treatment options, including chemotherapy and Lu-177 therapy. (WARMTH Act, The Lancet Oncology)
A reactor platform capable of supporting the upstream isotope pathway can become strategically relevant because it helps address a real bottleneck: reliable production of precursor inventory over time.
Isotope capability is not a separate business bolted onto the reactor. It emerges from the same fuel-cycle and reactor-architecture logic that underpins the broader platform.
As thorium-bearing fuel is irradiated over time, it can create a pathway toward the accumulation of strategically relevant isotope inventory, including Thorium-229, within the fuel system. Its full value increases as downstream recovery, handling, and processing capabilities mature.
The TGR can be configured with dedicated isotope-breeding channels designed specifically to support the accumulation of strategically relevant isotope inventory over time. The thesis does not depend entirely on broad fuel-cycle reprocessing becoming commercially viable first.
At a high level, the isotope logic is straightforward. Thorium-bearing material is irradiated within the reactor system. That irradiation pathway can contribute to the formation of Thorium-229 inventory, which sits upstream of Actinium-225.
Steps 1 through 3 occur as a natural consequence of reactor operation on thorium-bearing fuel. Th-229 inventory accumulates within thorium-bearing fuel, stored safely inside spent TRISO pebbles in dry cask storage.
Steps 4 and 5 shift from reactor-side production to downstream recovery, purification, and medical-use deployment. Realizing clinical or commercial value still depends on processing capability, regulatory approval, and GMP-compliant supply chain infrastructure.
Reactor-side isotope production pathways can be engineered into the TGR architecture itself, whether through thorium-compatible fuel regions, dedicated breeding channels, or both.
Downstream separation, qualification, handling, and medical-use commercialization still depend on processing capability, infrastructure, and regulatory approval. The reactor creates inventory. Realizing medical value requires downstream capability.
The TGR architecture supports multiple extraction approaches, each grounded in established practice.
Spent thorium fuel can yield Th-229 through established chemical separation techniques.
The core architecture can accommodate dedicated channels for targeted irradiation and removal, allowing isotope-bearing material to be harvested without interrupting reactor operations.
OPG and BWXT Medical produce Molybdenum-99 at Darlington Nuclear using a target delivery system that harvests isotopes while the reactor is still running.
Bruce Power produces Lutetium-177 from its commercial CANDU reactors through a dedicated Isotope Production System.
Supply is sourced primarily from aging government stockpiles of U-233 at Oak Ridge National Laboratory and a small number of accelerator-based programs. Clinical demand is growing rapidly as targeted alpha therapy advances through trials for prostate cancer, leukemia, and other indications.
Primarily sourced from legacy U-233 stockpiles. Supply has not scaled to meet rising clinical demand.
The market is already pricing in a future where targeted alpha therapy reaches clinical scale. The key bottleneck to wider adoption is supply.
For Thorium Atomics, the significance of isotope capability is not that it changes the purpose of the reactor. It does not.
The TGR is being built to solve hard energy problems first: high-temperature industrial heat, firm dispatchable power, long-term fuel diversification, and a more resilient nuclear fuel pathway over time.
What isotope capability adds is a second strategic layer. The same platform that addresses hard energy constraints may also create future value through medically and strategically relevant isotope pathways. Isotope production sits alongside fuel diversification as part of a broader strategy to strengthen the long-term value of a thorium-capable reactor platform.
Thorium Atomics is not presenting isotope production as the primary basis for the reactor case. Nor are we presenting it as a near-term commercial claim detached from the realities of processing, infrastructure, and regulation.
We are saying something narrower and more serious: a thorium-capable reactor platform can be designed not only for energy production, but also to support strategically relevant isotope pathways over time, through both fuel-cycle accumulation and dedicated breeding architecture.
Core case first. Strategic extension second.
Process heat, siting logic, and commercial offtake structures.
Contact →Qualified strategic, institutional, and capital partner discussions.
Contact →